Showing posts with label a/h5n1. Show all posts
Showing posts with label a/h5n1. Show all posts

Tuesday, June 9, 2026

Avian #Influenza #Report - May 31 – June 6 '26 (Wk 23) (#HK CHP, June 9 '26): 2 new human #H5N1 virus cases in #Bangladesh, #India; 1 new case of H9N2 virus in #China



(...)

    -- Bangladesh

        ° Avian influenza A(H5N1) 

            ° Sylhet Division

                - The case involved a child with symptom onset on March 27, 2026.  

                - The patient was admitted to a hospital on March 28 for treatment of measles with bronchopneumonia, and was discharged on March 30. 

                - Epidemiological investigations revealed the case had exposure to household poultry.   

                - No additional cases were reported among the identified contacts.  

    -- India

        ° Avian influenza A(H5N1)

            - The case involved a child who developed symptoms and was admitted to a hospital on March 19, 2026. 

            - The patient was discharged on March 23.  

            - Epidemiological investigations revealed the case likely had indirect exposure to poultry. 

            - No additional cases were reported among the identified contacts. 

        -- China

            ° Avian influenza A(H9N2)

                ° Yunnan Province

                    - A 4-year-old boy with onset on May 17, 2026. 

(...)


Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk23.pdf

____


Saturday, June 6, 2026

The #canine respiratory #epithelium is a permissive #ecosystem for #influenza interspecies #transmission and emergence

 


Abstract

The outcome of virus spillover ranges from dead-end infections to pandemics and is underpinned by host-pathogen interactions as well as evolutionary and epidemiological processes. The emergence of novel influenza A viruses (IAVs) has been associated with reassortment events involving multiple species, highlighting the importance of reservoir and intermediate hosts in viral emergence. Highly pathogenic H5N1 IAVs of the 2.3.4.4b genotype have caused a panzootic affecting a broad range of mammals. The role of dogs -arguably the most popular companion animal and a natural host of IAVs- in the ecology of IAVs under this new zooepidemiological scenario is unknown. To address this, we characterised the glycome of the dog respiratory epithelium, infected canine tracheal explants with multiple IAVs (including canine H3N2 and H3N8, equine H3N8, avian H3N8 and H5N1, swine H1N1, human H1N1 and H3N2, and bovine H5N1 viruses), and determined their cellular tropism. We show that the respiratory tract of dogs presents abundant sialylated glycans known to act as IAV receptors. Further, most IAVs (including 2.3.4.4b viruses) infected and replicated in dog tracheas, targeting mainly ciliated cells. Serological testing showed evidence of influenza spillover infections in dogs from the UK. Overall, our results show that the canine respiratory tract can provide a suitable environment for the generation of new IAVs. Given the multi-host contact networks of dogs in nature, they could act as recipients, bridging hosts, and/or mixing vessels for multiple IAV lineages, playing a central role in the ecology of influenza emergence.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Medical Research Council, https://ror.org/03x94j517, MR/Y03368X/1, MC_UU_0034/2, MC_UU_0034/3

Biotechnology and Biological Sciences Research Council, BB/Y007093/1, BB/Y007298/1, BBS/E/PI/230001A, BBS/E/PI/230002A, BBS/E/PI/230002B, BBS/E/PI/230001C

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.06.04.730051v1

____

Friday, June 5, 2026

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, June 5 '26)

 


{Excerpt}

(...)

Time Period: May 24, 2026 - May 30, 2026

    -- A(H5) Detection6 site(s) (1.4%)

    -- No Detection421 site(s) (98.6%)

    -- No samples69 site(s)


{Click on Image to Enlarge}



(...)

Source: 


Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

#Influenza at the #human - #animal #interface - #Summary and #risk #assessment, from 1 April to 8 May 2026{1} (#WHO, June 5 '26)

 


New human cases{2}: 

    ° From 1 April to 8 May 2026, based on reporting date, detections of influenza A(H5N1) in three humans, influenza A(H5N6) in one human, influenza A(H9N2) in five humans, and influenza A(H1N2) variant ((H1N2)v) virus in one human were reported officially. 


Circulation of influenza viruses with zoonotic potential in animals

    ° High pathogenicity avian influenza (HPAI) events in poultry and non-poultry animal species continue to be reported to the World Organisation for Animal Health (WOAH).{3} 

    ° The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with pandemic potential.{4} 

    ° Additionally, low pathogenicity avian influenza viruses as well as swine influenza viruses continue to circulate in animal populations. 


Risk assessment{5}: 

    ° Sustained human to human transmission has not been reported associated with the above-mentioned human infection events

    ° Based on information available at the time of this risk assessment update, the overall public health risk from currently known influenza A viruses detected at the human-animal interface has not changed and remains low

    ° At present, these viruses are not thought to be capable of sustained human-to-human transmission, although this could change as they evolve.  

    ° Although human infections with viruses of animal origin are infrequent, they are not unexpected at the human-animal interface.  


IHR compliance{6}: 

    ° This includes any influenza A virus that has demonstrated the capacity to infect a human and its haemagglutinin (HA) gene (or protein) is not a mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human population. 

    ° Information from these notifications is critical to inform risk assessments for influenza at the human-animal interface.  


Avian influenza viruses in humans A(H5N1), Bangladesh  

    ° On 23 April 2026, Bangladesh notified WHO of one laboratory-confirmed human case of avian influenza A(H5) infection in a child from Sylhet Division. 

    ° The patient developed fever and cough on 27 March 2026 and was admitted to hospital on 28 March with a clinical diagnosis of measles with bronchopneumonia

    ° As part of hospital-based influenza surveillance, a sample was collected on 29 March and received by the Institute of Epidemiology, Disease Control and Research (IEDCR) on 20 April. 

    ° The sample tested positive for influenza A(H5N1) on the same day by real-time reverse transcription polymerase chain reaction (RT-PCR). 

    ° The patient was discharged on 30 March

    ° No additional cases were reported among identified contacts

    ° Epidemiological investigations identified exposure to household poultry.  

    ° This is the second laboratory-confirmed human case of avian influenza A(H5N1) reported in Bangladesh in 2026. 


A(H5N1), Cambodia 

    ° On 22 April 2026, Cambodia notified WHO of one laboratory-confirmed human case of avian influenza A(H5) infection in a 66-year-old woman with comorbidities from Svay Rieng province. 

    ° The patient developed symptoms on 15 April 2026 and was admitted to district hospital on 16 April and provincial hospital the next day. 

    ° As part of severe acute respiratory infection surveillance, a sample was collected on 17 April and received by the National Institute of Public Health on 21 April. 

    ° The sample tested positive for influenza A(H5N1) on the same day by real-time RT-PCR, and the result was confirmed by Institut Pasteur du Cambodge on 22 April. 

    ° The patient died on 22 April

    ° No additional cases were reported among 15 identified contacts

    ° Epidemiological investigations identified exposure to sick and dead household chickens prior to illness onset.  

    ° Four human infections with A(H5N1) viruses have been confirmed in Cambodia in 2026, including one fatal case. 

    ° Influenza A(H5N1) viruses continue to be detected in domestic birds in Cambodia in 2026, including in areas where human cases have been detected. 

    ° Where the information is available, the genetic sequence data from the viruses from the human cases closely matches that from recent local animal viruses and are identified as clade 2.3.2.1e viruses

    ° From the information available thus far on these recent human cases, there is no indication of human-to-human transmission of the A(H5N1) viruses.   


A(H5N1), India 

    ° On 27 March 2026, India notified WHO of one laboratory-confirmed human case of avian influenza A(H5N1) infection in a child from West Bengal state. 

    ° The patient developed fever and cough and was admitted to hospital on 19 March. 

    ° The patient was discharged on 23 March

    ° Laboratory testing at the Indian Council of Medical Research (ICMR) National Institute of Virology in Pune confirmed influenza A(H5N1). 

    ° Genomic sequencing identified the virus as belonging to clade 2.3.2.1a, closely related to strains previously reported from Bangladesh and India in 2025. 

    ° No additional cases were reported among identified contacts. 

    ° Epidemiological investigations identified likely indirect exposure to poultry.  

    ° This is the first laboratory-confirmed human case of avian influenza A(H5N1) reported in India in 2026


A(H5N6), China 

    ° On 29 April 2026, China notified WHO of one laboratory-confirmed human case of avian influenza A(H5N6) infection in a 55-year-old female with comorbidities from Chongqing Municipality. 

    ° She had onset of symptoms on 16 April 2026 and was hospitalized on 23 April with severe pneumonia.  

    ° The patient died on 3 May 2026

    ° She had slaughtered and prepared poultry prior to onset of symptoms. 

    ° Environmental samples collected from the food preparation tools at the patient’s residence tested positive for influenza A(H5). 

    ° No further cases were detected among contacts of the patient. 

    ° This is the first laboratory-confirmed human case of infection with an A(H5N6) virus detected since 2024


    According to reports received by WOAH, various influenza A(H5) subtypes continue to be detected in wild and domestic birds in Africa, the Americas, Asia and Europe

    Infections in non-human mammals are also reported, including in marine and land mammals.{7} 

    A list of bird and mammalian species affected by HPAI A(H5) viruses is maintained by FAO.{8}   


Risk assessment for avian influenza A(H5) viruses:   

    1. What is the current global public health risk of additional human cases of infection with avian influenza A(H5) viruses?   

        ° Most human infections so far have been reported in people exposed to A(H5) viruses, for example, through contact with infected poultry or contaminated environments, including live poultry markets, and occasionally infected mammals and contaminated environments. 

        ° As long as the viruses continue to be detected in animals and related environments humans are exposed to, further human cases associated with such exposures are expected but remain unusual. 

        ° The impact for public health if additional sporadic cases are detected is minimal

        ° The current overall global public health risk is low

    2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H5) viruses related to the events above?   

        ° No sustained human-to-human transmission has been identified associated with the recent reported human infections with avian influenza A(H5) viruses. 

        ° There has been no reported human-to-human transmission of A(H5N1) viruses since 2007, although there may be gaps in investigations. 

        ° In 2007 and the years prior, small clusters of A(H5) virus infections in humans were reported, including some involving health care workers, where limited human-to-human transmission could not be excluded; however, sustained human-to-human transmission was not reported.   

        ° Current evidence suggests that influenza A(H5) viruses related to these events did not acquire the ability to efficiently transmit between people.  

    3. What is the likelihood of international spread of avian influenza A(H5) viruses by travellers?   

        ° Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

        ° If this were to occur, further communitylevel spread is considered unlikely as current evidence suggests these viruses have not acquired the ability to transmit easily among humans.   


A(H9N2), China  

    ° Between 7 April and 6 May 2026, China notified WHO of five laboratory-confirmed cases of A(H9N2) virus infection. 

    ° The first case had comorbidities and developed severe pneumonia

    ° All the cases except the child from Jiangxi had exposure to live bird markets or household birds. 

    ° Samples from environments associated with the likely area of exposure of some of these cases tested positive for A(H9) viruses. 

    ° No further cases were detected among contacts of these cases.   


Risk assessment for avian influenza A(H9N2):  

    1. What is the global public health risk of additional human cases of infection with avian influenza A(H9N2) viruses?  

        ° Most human cases follow exposure to the A(H9N2) virus through contact with infected poultry or contaminated environments

        ° Most human infections of A(H9N2) to date have resulted in mild clinical illness

        ° Since the virus is endemic in poultry in multiple countries in Africa and Asia, additional human cases associated with exposure to infected poultry or contaminated environments are expected but remain unusual. 

        ° The impact to public health if additional sporadic cases are detected is minimal

        ° The overall global public health risk is low.  

    2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H9N2) viruses related to these events?  

        ° At the present time, no sustained human-to-human transmission has been identified associated with the recently reported human infections with A(H9N2) viruses. 

        ° Current evidence suggests that A(H9N2) viruses from these cases did not acquire the ability of sustained transmission among humans.  

    3. What is the likelihood of international spread of avian influenza A(H9N2) virus by travellers?  

        ° Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

        ° If this were to occur, further community level spread is considered unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired the ability to transmit easily among humans.  


Swine influenza viruses in humans  

Influenza A(H1N2)v, United States  

    ° On 2 May 2026, the United States notified WHO of a laboratory-confirmed case of A(H1N2)v influenza virus infection in an individual under 18 years of age from Nebraska

    ° The patient had onset of mild illness in early April 2026 and has recovered. 

    ° A respiratory specimen collected in mid-April as part of routine surveillance was sent to the US Centers for Disease Control and Prevention (CDC). 

    ° Real-time RT-PCR testing by CDC determined the sample was positive for an influenza A(H1N2)v virus

    ° Additional genetic and virologic characterization is currently underway

    ° Local public health investigations did not identify direct or indirect exposure to swine. 

    ° One household contact had mild respiratory illness also in early April but no additional cases of A(H1N2)v were identified at the time of reporting.{9} 

    ° This is the first human A(H1N2)v infection detected in the United States in 2026.  


Risk assessment for swine influenza viruses:   

    1. What is the public health risk of additional human cases of infection with swine influenza viruses?   

        ° Swine influenza viruses circulate in swine populations in many regions of the world. 

        ° Depending on geographic location, the genetic characteristics of these viruses differ. 

        ° Most human cases are exposed to swine influenza viruses through contact with infected animals or contaminated environments. 

        ° Human infection tends to result in mild clinical illness in most cases. 

        ° Since these viruses continue to be detected in swine populations, further human cases are expected. 

        ° The impact to public health if additional sporadic cases are detected is minimal

        ° The overall risk of additional sporadic human cases is low.   

    2. What is the likelihood of sustained human-to-human transmission of swine influenza viruses?    

        ° No sustained human-to-human transmission was identified associated with the event described above. 

        ° Current evidence suggests that contemporary swine influenza viruses have not acquired the ability of sustained transmission among humans.  

    3. What is the likelihood of international spread of swine influenza viruses by travellers?    

        ° Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

        ° If this were to occur, further community level spread is considered unlikely as current evidence suggests that these viruses have not acquired the ability to transmit easily among humans.  


Overall risk management recommendations

    ° Surveillance and investigations 

        Due to the constantly evolving nature of influenza viruses, WHO continues to stress the importance of global strategic surveillance in animals and humans to detect virologic, epidemiologic and clinical changes associated with circulating influenza viruses that may affect human (or animal) health. Continued vigilance is needed within affected and neighbouring areas to detect infections in animals and humans. Close collaboration with the animal health and environment sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. WHO has published guidance on surveillance for human infections with avian influenza A(H5) viruses. 

        As the extent of influenza virus circulation in animals is not clear, epidemiologic and virologic surveillance and the follow-up of suspected human cases should continue systematically. Guidance on investigation of non-seasonal influenza and other emerging acute respiratory diseases has been published on the WHO website. 

        Countries should increase avian influenza surveillance in domestic and wild birds, enhance surveillance for early detection in cattle populations in countries where HPAI is known to be circulating, include HPAI as a differential diagnosis in non-avian species, including cattle and other livestock populations, with high risk of exposure to HPAI viruses; monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in all animal species, including unusual hosts, to WOAH and other international organizations, share genetic sequences of avian influenza viruses in publicly available databases, implement preventive and early response measures to break the HPAI transmission cycle among animals through movement restrictions of infected livestock holdings and strict biosecurity measures in all holdings, employ good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals.{10} More guidance can be found from WOAH and FAO. 

        When there has been human exposure to a known outbreak of an influenza A virus in domestic poultry, wild birds or other animals – or when there has been an identified human case of infection with such a virus – enhanced surveillance in potentially exposed human populations becomes necessary. Enhanced surveillance should consider the health care seeking behaviour of the population, and could include a range of active and passive health care and/or communitybased approaches, including: enhanced surveillance in local influenza-like illness (ILI)/SARI systems, active screening in hospitals and of groups that may be at higher occupational risk of exposure, and inclusion of other sources such as traditional healers, private practitioners and private diagnostic laboratories. 

        Vigilance for the emergence of novel influenza viruses with pandemic potential should be maintained at all times including during a non-influenza emergency. In the context of the cocirculation of SARS-CoV-2 and influenza viruses, WHO has updated and published practical guidance for integrated surveillance. 

    ° Notifying WHO 

        All human infections caused by a new subtype of influenza virus are notifiable under the International Health Regulations (IHR, 2005).{11,12} State Parties to the IHR (2005) are required to immediately notify WHO of any laboratory-confirmed{13} case of a recent human infection caused by an influenza A virus with the potential to cause a pandemic{14}. Evidence of illness is not required for this report. Evidence of illness is not required for this report. 

        WHO published the case definition for human infections with avian influenza A(H5) virus requiring notification under IHR (2005): https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions

    ° Virus sharing and risk assessment 

        It is critical that these influenza viruses from animals or from humans are fully characterized in appropriate animal or human health influenza reference laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP) Framework, Member States are expected to share influenza viruses with pandemic potential on a timely basis{15} with a WHO Collaborating Centre for influenza of GISRS. The viruses are used by the public health laboratories to assess the risk of pandemic influenza and to develop candidate vaccine viruses.  

        The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides an in-depth assessment of risk associated with some zoonotic influenza viruses – notably the likelihood of the virus gaining human-to-human transmissibility, and the impact should the virus gain such transmissibility. TIPRA maps relative risk amongst viruses assessed using multiple risk elements. The results of TIPRA complement those of the risk assessment provided here, and those of prior TIPRA risk assessments are published at http://www.who.int/teams/global-influenza-programme/avianinfluenza/tool-for-influenza-pandemic-risk-assessment-(tipra).  Risk reduction 

        Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should avoid contact with animals that are sick or dead from unknown causes, including wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.  Eggs, poultry meat and other poultry food products should be properly cooked and properly handled during food preparation. Due to the potential health risks to consumers, raw milk should be avoided. WHO advises consuming pasteurized milk. If pasteurized milk isn’t available, heating raw milk until it boils makes it safer for consumption. 

        WHO has published practical interim guidance to reduce the risk of infection in people exposed to avian influenza viruses. 

    ° Trade and travellers 

        WHO advises that travellers to countries with known outbreaks of animal influenza should avoid farms, contact with animals in live animal markets, entering areas where animals may be slaughtered, or contact with any surfaces that appear to be contaminated with animal excreta. Travelers should also wash their hands often with soap and water. All individuals should follow good food safety and hygiene practices.  

        WHO does not advise special traveller screening at points of entry or restrictions with regards to the current situation of influenza viruses at the human-animal interface. For recommendations on safe trade in animals and related products from countries affected by these influenza viruses, refer to WOAH guidance.  


Links:  

    WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza 

    WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic) 

    WHO Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2 

    WHO Public health resource pack for countries experiencing outbreaks of influenza in animals:  https://www.who.int/publications/i/item/9789240076884 

    Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO  https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus 

    Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)virus 

    World Organisation of Animal Health (WOAH) web page: Avian Influenza  https://www.woah.org/en/home/ 

    Food and Agriculture Organization of the United Nations (FAO) webpage: Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/ 

    WOAH/FAO Network of Expertise on Animal Influenza (OFFLU) http://www.offlu.org/ 

(...)


{1} This summary and assessment covers information confirmed during this period and may include information received outside of this period. 

{2} For epidemiological and virological features of human infections with animal influenza viruses not reported in this assessment, see the reports on human cases of influenza at the human-animal interface published in the Weekly Epidemiological Record here.  

{3} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{4} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential

{5} World Health Organization (2012). Rapid risk assessment of acute public health events. World Health Organization. Available at: https://iris.who.int/handle/10665/70810

{6} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005). Available at: https://www.who.int/publications/m/item/case-definitions-for-the-four-diseases-requiring-notification-towho-in-all-circumstances-under-the-ihr-(2005).  

{7} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{8} Food and Agriculture Organization of the United Nations. Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential/bird-species-affected-by-h5nx-hpai/en

{9} US CDC. FluView week 17, 8 May 2026 (https://www.cdc.gov/fluview/surveillance/2026-week-17.html). 

{10} World Organisation for Animal Health. Statement on High Pathogenicity Avian Influenza in Cattle, 6 December 2024 (https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/). 

{11} World Health Organization. International Health Regulations (2005), as amended through resolutions WHA67.13 (2014), WHA75.12 (2022), and WHA77.17 (2024) (https://apps.who.int/gb/bd/pdf_files/IHR_20142022-2024-en.pdf). 

{12} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005) (https://www.who.int/publications/m/item/casedefinitions-for-the-four-diseases-requiring-notification-to-who-in-all-circumstances-under-the-ihr-(2005)). 

{13} World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza (2011) (https://apps.who.int/iris/handle/10665/44518). 

{14} World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits, 2nd edition (https://iris.who.int/handle/10665/341850). 

{15} World Health Organization. Operational guidance on sharing influenza viruses with human pandemic potential (IVPP) under the Pandemic Influenza Preparedness (PIP) Framework (2017) (https://apps.who.int/iris/handle/10665/259402). 

Source: 


Link: https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment--8-may-2026

____

Broad heterologous #protection against #Influenza A viruses by an adjuvant-free modular mucosal T-cell #vaccine #platform

 


Abstract

Rapid antigenic evolution of Influenza A viruses (IAVs) enables their escape from strain-specific vaccine immunity, underscoring the need for broadly protective strategies. Here, we describe a modular, adjuvant-free mucosal vaccine platform that elicits potent and cross-protective T cell immunity. The approach uses overlapping CD4+ and CD8+ epitope-dense regions from the consensus IAV M1 and NP proteins, identified through computational and functional screening. These peptides are delivered using polylactic-co-glycolic acid (PLGA) microparticles, engineered for selective uptake by antigen-presenting cells and enabling sustained, pH-responsive antigen release. This design enhances antigen processing and MHC cross-presentation, functionally substituting for a conventional adjuvant. This formulation drives robust activation of primed human as well as murine CD4+ and CD8+ T cells and confers broad protection against homologous (H1N1, H3N2) as well as heterologous (H5N1) IAV strains in immunized mice. Overall, this adjuvant-free dose-sparing platform establishes an adaptable framework for next-generation broadly-protective vaccines against rapidly evolving viruses.


Competing Interest Statement

R.T.Y. and S.T. are co-inventors on an unpublished patent titled Immunogenic peptide(s), composition(s) and application(s) thereof broadly protective against Influenza, Indian patent application number 202541082426. The other authors declare that they have no competing interests.


Funder Information Declared

DBT-ENDFLU, BT/IN/EU-INF/15/RV/19-20

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.03.29.715080v2

____

Wednesday, June 3, 2026

CEIRR #Risk #Assessment Pipeline executive reports on #H5N1 highly pathogenic avian influenza 2.3.4.4b, swine H1 1B.2, and #H9N2 low pathogenicity avian influenza B4.7.2

 


ABSTRACT

The Centers of Excellence for Influenza Research and Response (CEIRR) Risk Assessment Pipeline (RAP) integrates surveillance, phenotypic analysis, and computational modeling across six CEIRR centers to evaluate the pandemic potential of influenza A viruses. By generating coordinated data sets from wild and domestic animals and linking them to viral evolution and functional traits, CEIRR RAP supports the Centers for Disease Control and Prevention’s and the World Health Organization’s risk-assessment efforts. The RAP’s data packages thereby enable evidence-based prioritization of global influenza preparedness and response strategies.

Source: 


Link: https://journals.asm.org/doi/10.1128/jvi.00545-26

____

#Senegal - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification

 


The farm is part of mixed-species premises with several types of animals, including ducks, broiler chickens, Goliath chickens, and rabbits. Two male breeding ducks were purchased at the Passy market on May 8, 2026, in the department of Foundiougne, located in the Fatick region, to restock the flock and ensure mating with the females. One of the newly introduced adult males died from the disease, while the other survived. The quarantine period for the two new ducks was not applied properly. The first symptoms appeared on May 11, 2026, and the first deaths occurred on May 12, 2026. In total, among the ducks, 29 deaths were recorded out of a flock of 50, representing a mortality rate of 58%. As for the Goliath chickens, out of a flock of 11, 4 deaths were recorded, representing a mortality rate of 36.36%. Additionally, 7 other birds were culled by the manager following the appearance of clinical signs.

Source: 


Link: https://wahis.woah.org/#/in-review/7593

____

Saturday, May 30, 2026

Sex differences in #vaccine-induced #neuraminidase cross-recognition and #protection against #H5N1 in mice

 


Abstract

Despite concerns about the spread and pandemic potential of H5N1, there is no commercial H5N1 vaccine. Seasonal influenza vaccines offer some cross-protection against H5N1, but to date there has been no consideration of whether protection differs between the sexes. We investigated immune responses and protection in adult male and female C57BL/6 mice following vaccination with either inactivated H1N1 or H5N1 (LAIV backbone) virus vaccines. Vaccination induced strong homologous antibody responses, with females generating greater total IgG than males against both H1N1 and H5N1 vaccine, which was primarily mediated by greater IgG responses to neuraminidase (NA) than hemagglutinin (HA) protein. IgG cross-recognition of H1N1 also was greater among H5N1 vaccinated females and was primarily caused by greater IgG responses to N1. IgG2b and IgG2c were the primary isotypes generated in response to these vaccines, with females having greater IgG2b responses and greater binding to FcγRIV for avian and human NA than males in response to both homologous and heterologous vaccination. Antibody-dependent complement deposition was measured as an FcR-mediated non-neutralizing response against HA and NA and was robust in both sexes. Vaccinated females had greater neutralizing antibody titers than males against the homologous vaccine virus, with limited cross-neutralizing antibodies detected in either sexes. Neuraminidase inhibition titers were greater in vaccinated females than males against the heterologous virus following H1N1 vaccination and against both the vaccine and heterologous viruses following H5N1 vaccination. When H1N1 and H5N1 vaccinated mice were challenged with a lethal dose of A/Texas/37/2024 H5N1, all H5N1 vaccinated mice were protected, regardless of sex. Among H1N1 vaccinated mice, while both sexes were protected against disease, H1N1 vaccinated females cleared virus faster than their male counterparts. These findings highlight that female-biased NA-specific antibodies result in greater cross-protection and should be considered in studies of influenza vaccines.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

NIH/NIAID Johns Hopkins Center of Excellence for Influenza Research and Response, 75N93021C00045

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.05.26.728011v1

____

Friday, May 29, 2026

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, May 29 '26)

 


{Excerpt}

(...)

Time Period: May 17, 2026 - May 23, 2026

-- A(H5) Detection7 site(s) (1.6%)

-- No Detection438 site(s) (98.4%)

-- No samples49 site(s)


{Click on Image to Enlarge}



(...)

Source: 


Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

Wednesday, May 27, 2026

Two #epidemics, one #genotype, different outcomes: evolutionary #changes of Avian #Influenza #H5N1, genotype EA-2024-DI

 


Abstract

Since 2020, high pathogenicity avian influenza H5Nx viruses of clade 2.3.4.4b have become enzootic in Europe, causing recurrent epidemic waves characterized by extensive reassortment events. Here, we describe the emergence of a single high-fitness genotype (EA-2024-DI) that has driven two consecutive waves, evolving into distinct sub-lineages. While its circulation is ongoing, during the 2025-2026 wave it caused an unprecedented number of cases in wild birds. Using phylodynamic analyses of a large dataset of genomic sequences, we compared the spatial diffusion and host transmission pattern of the EA-2024-DI sub-lineages across the three most recent epidemic waves (2023-2024, 2024-2025 and 2025-2026). We show that the genotype has persisted over time and has spread primarily through wild Anseriformes, but with a marked change in the transmission patterns between the different waves and a shift in the epicenter from Eastern to Central Europe, the latter having emerged as an important hub for virus diffusion throughout Europe. Our results reveal a recent increase in the frequency of viruses from wild and domestic mammals carrying mutations enhancing virus replication in mammalian hosts, highlighting the importance of proactive monitoring of this group of hosts to better understand its role in the virus ecology and evolution.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Funded by the European Union under grant agreement (101084171) - (Kappa-Flu). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or REA. Neither the European Union nor the granting authority can be held responsible for them

Support for this work was provided by the European Union within the framework of the activities foreseen by the European Union Reference Laboratory for Avian Influenza and Newcastle Disease under grant agreement 101201937

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.05.25.727580v1

____

Monday, May 25, 2026

Clade 2.3.4.4b #H5N1 #HPAIV from Migratory #Birds in Beidaihe #Wetland, North #China

 


Abstract

During 2022–2024, a highly pathogenic avian influenza virus (HPAIV) H5N1 strain, designated A/Seagull/Hebei/qhd6/2024 (H5N1), was isolated from migratory birds in Beidaihe National Wetland Park, North China. Phylogenetic analyses revealed that its hemagglutinin (HA) gene belongs to the 2.3.4.4b clade, while the neuraminidase (NA) gene and internal genes clustered with strains originating from multiple continents, consistent with a transcontinental reassortment event. The virus also exhibited 90.1–98.1% nucleotide homology with human-derived H5N1 isolates. Molecular characterization identified key virulence-associated mutations, including the classic HPAIV HA cleavage site, HA-T160A (associated with enhanced human receptor-binding capacity), and NA-I117T (potentially linked to drug resistance). BALB/c mouse infection experiments confirmed systemic replication and high pathogenicity of strain qhd6, with a 50% lethal dose (LD50) of 0.95 log10EID50/mL. Antigenic analysis revealed good cross-reactivity with the widely used H5-Re14 vaccine strain. This study reports the identification, in Beidaihe National Wetland Park, of an HPAIV H5N1 strain whose genetic characteristics suggest intercontinental reassortment and indicate cross-species transmission risk. It clarifies the genetic characteristics and pathogenicity of this strain, providing an important theoretical and practical basis for precise surveillance, risk early warning, and comprehensive prevention and control of AIV at migratory bird stopover sites in North China.

Source: 


Link: https://www.mdpi.com/1999-4915/18/6/595

____

Predicting #Influenza Virus #Host #Tropism and Zoonotic #Spillover #Risk from #Protein Sequences

 


Abstract

Novel infectious diseases, predominantly originating from non-human animals, pose a significant threat to global public health and economic stability. Avian influenza virus presents an especially significant challenge due to its high mortality rates and spillover capability into new host species. Recent H5N1 spillover events into poultry and cattle resulted in massive economic burden and increased human health risk. Traditional methods of disease surveillance rely on reactive case detection and pathogen characterization, providing insufficient lead time for effective intervention. Computational tools that allow efficient and proactive prediction of zoonotic potential are critical in mitigation of influenza outbreaks and identification of strains with human spillover risk. Existing models predicting influenza virus subtypes or host have been developed; however, the complexity of spillover events, including the non-binary nature of zoonotic potential, limits the capabilities of these models. In the approach reported here, rich protein language model embeddings were generated from ESM-2 for each protein in influenza virus strains and used to predict the protein host tropism probabilities across nine animal families. The protein host tropism model achieved weighted precision and recall scores of 0.95 and 0.95, respectively. We then constructed a zoonotic risk prediction model using the outputs from the protein host tropism prediction model to classify the strains into six classifications: avian, mammal, human, avian-to-human zoonotic, avian-to-mammal zoonotic, or mammal-to-human zoonotic. The average weighted precision and recall scores for this model were 0.90 and 0.90, respectively. This framework advances the prediction of influenza zoonotic risk by being agnostic to influenza subtype, incorporating non-human mammals and mammal zoonotic spillover classifications, and using the full influenza proteome to capture the complexity of spillover dynamics.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.05.21.726772v1

_____

Sunday, May 24, 2026

Dairy #cows infected with #influenza #H5N1 reveals low infectious dose and #transmission #barriers

 


Abstract

Highly pathogenic avian influenza A(H5N1) virus exhibits a strong tropism for the bovine mammary gland, challenging our understanding of influenza A virus host range and tissue specificity. We performed experimental studies with an influenza A(H5N1) B3.13 genotype virus in female lactating dairy cattle to define the infectious dose, routes of exposure, and factors linked to morbidity and mortality. Here, we demonstrate that intramammary inoculation with as few as 10 TCID50 establishes a robust infection and shedding of high-titer virus in milk. Despite this low infectious dose, H5N1 does not readily transmit via contaminated milking equipment and close contact with infected animals. High-dose intramammary exposure results in severe disease and mortality, while respiratory and oral exposures are less likely to establish productive infection and associated morbidity. This study challenges current hypotheses of H5N1 transmission on dairy farms, raising important questions about potential agent, host, or environmental cofactors contributing to viral spread.

Source: 


Link: https://www.nature.com/articles/s41467-026-73490-6

____

Spatiotemporal #Dynamics of Highly Pathogenic Avian #Influenza #H5 Virus Introductions and Regional Spread in the Republic of #Korea

 


Abstract

Highly pathogenic avian influenza (HPAI) viruses from clade 2.3.4.4 have caused recurrent outbreaks in poultry since 2014. In the Republic of Korea, clade 2.3.4.4b viruses have driven five epidemic waves, yet the factors underlying HPAI introduction and farm-to-farm spread remain poorly understood. We compiled hemagglutinin gene sequences of clade 2.3.4.4b viruses from wild birds and poultry in the Republic of Korea (October 2016–March 2024) and reconstructed dispersal dynamics using Bayesian phylogeography. Dispersal patterns suggest that domestic duck farms in the western provinces likely form a key interface for spillover from wild birds into poultry. Mixed-effects generalized linear models showed that both wild-to-poultry and farm-to-farm transition rates were positively associated with the number of poultry farms in the destination province, while wild-to-poultry rates were further associated with higher avian influenza virus infection probability among wild birds. Wild-to-poultry transition rates were lower in 2020–2024 than in 2016–2018, which may reflect strengthened interventions. These findings suggest that poultry farm abundance and introduction pressure from wild birds jointly shape the spatial dynamics of HPAI introduction and spread. More broadly, these factors may provide operational indicators to guide risk-based surveillance and control strategies.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.05.21.726857v1

____

Friday, May 22, 2026

Molecular Characterization of #H5N1 Clade 2.3.4.4B Virus in Vaccinated Layer #Chickens

 


Abstract

The global emergence of the avian influenza virus (AIV) H5N1 clade 2.3.4.4B since 2016 has caused substantial losses in wild bird and poultry populations, along with heightened risks of transmission to humans and other mammals. Vaccination of poultry has been a key strategy to curb the virus’s spread and mitigate its socioeconomic impact. This report describes an outbreak of high pathogenicity avian influenza virus (HPAIV) H5N1 clade 2.3.4.4B in a flock of 15,000 brown layer chickens (170 days old), all of which had received a four-dose vaccination regimen with H5N1/H5N8 commercial vaccines at 17, 50, 100, and 125 days of age. Despite this vaccination history, H5N1 infection was confirmed approximately seven weeks post-vaccination. H5N1 infection was confirmed by RT-qPCR, virus isolation, and full genome sequencing covering all eight gene segments, followed by phylogenetic and molecular analyses. Clinical signs included reduced feed intake, decreased egg production, and a cumulative mortality rate of 35% over 52 days. Hemagglutination inhibition (HI) testing with various H5 antigens revealed inconsistent antibody titers (geometric mean: 4.0 to 9.1 log2). Genetic analysis of the full-length HA and NA gene sequences further revealed strong similarity to contemporaneous H5N1 clade 2.3.4.4B strains circulating in Egypt, with multiple mutations in the HA head domain, particularly near immunogenic epitopes and receptor binding sites. These findings highlight the limitations of current vaccination strategies under conditions of antigenic mismatch and complex immunization schedules, emphasizing the need for improved vaccine matching and continuous molecular surveillance. To improve outbreak management in poultry, enhanced vaccination protocols, stringent biosecurity measures, and rigorous monitoring practices are critical.

Source: 


Link: https://www.mdpi.com/1999-4915/18/6/589

____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, May 22 '26)

 


{Excerpt}

(...)

Time Period: May 10, 2026 - May 16, 2026

    -- A(H5) Detection4 site(s) (1.0%)

    -- No Detection413 site(s) (99.0%)

    -- No samples81 site(s)


{Click on Image to Enlarge}



(...)

Source: 


Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

My New Space

Most Popular Posts